Avid Bioservices Inc (CDMO)

[cjgaddy]

Papa2000, another nice recap of TarvacinAV pre-clinical successes vs. Lassa Fever:

Peregrine CFO Paul Lytle 12-15-05 at the NYSSA “Biotech/Specialty Pharma Conf.”:

“This slide shows the results of a study by our researchers at UT-SW/Dallas; this is a hemorrhagic virus, Lassa Fever – it’s just like the Marburg, Ebola viruses, which fall under this hemorrhagic fever category. These animals on day 0 were treated with 2x the lethal dose of Lassa Fever. On day 7 we began treatment, when these animals were basically on death’s doorstep, very sick animals, losing weight. And, within a few days all of the control animals died. When you look at the animals that were treated with Tarvacin, we were able to save 50% of them, and this experiment has been repeated over and over again. What’s even more amazing, though, is that these animals were re-infected on day 117 with another lethal dose of the virus, without having any other Tarvacin antibody injected, and these animals basically acquired lasting immunity. And these animals for followed for several months thereafter. So, very encouraging results. We showed this to our SRB, our scientists internally, and they basically said we should get this into the clinic as soon as practical, and that’s what we did.”

He went on to hint at what’s coming:

”Based in the initial HepC study initiated in Aug2005, we are already planning add’l studies in HepC - two more studies: the 1st one will be a Ph. 1B repeat-dose study and the 2nd one will be a Ph. I/II Combo study with std. of care, such as Ribavirin or Interferon, and we’re working with our SRB right now in developing those studies. The info & safety we gain from these studies will help expedite the broad potential of this product in other viral indications - Influenza, CMV, HIV are indications that were are currently looking at... Regarding HIV, we know that we have positive binding to both HIV1 & HIV2. There are plans underway for important collaborations in HIV, and we expect announcements during 1H-2006…”
http://www.investorshub.com/boards/read_msg.asp?message_id=8917320

Remember, at the 10-24-05 SHM, CEO Steve King told us, “Tulane & Duke are working on Tarvacin for the treatment of HIV, which was the we time we heard "DUKE and TARVACIN" mentioned in the same breath.